UB Paderborn / Katalog / Suche / in CDI

Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD

The New England journal of medicine, 2020-07, Vol.383 (1), p.35-48

2020

Volltextzugriff (PDF)

Controlled Trial of Budesonide–Formoterol as Needed for Mild Asthma

The New England journal of medicine, 2019-05, Vol.380 (21), p.2020-2030

2019

Volltextzugriff (PDF)

Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease

Cochrane database of systematic reviews, 2014-03, Vol.2014 (3), p.CD010115

2014

Volltextzugriff (PDF)

Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma

The New England journal of medicine, 2016-09, Vol.375 (9), p.840-849

2016

Volltextzugriff (PDF)

Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial

The lancet respiratory medicine, 2018-05, Vol.6 (5), p.337-344

2018

Volltextzugriff (PDF)

Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPD

The New England journal of medicine, 2011-03, Vol.364 (12), p.1093-1103

2011

Volltextzugriff (PDF)

Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD)

Cochrane database of systematic reviews, 2017-02, Vol.2 (2), p.CD012066

2017

Volltextzugriff (PDF)

Effect of intravenous β-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trial

The Lancet (British edition), 2012, Vol.379 (9812), p.229-235

2012

Volltextzugriff (PDF)

β₂-Adrenergic agonists augment air pollution-induced IL-6 release and thrombosis

The Journal of clinical investigation, 2014-07, Vol.124 (7), p.2935-2946

2014

Volltextzugriff (PDF)

Serious Asthma Events with Budesonide plus Formoterol vs. Budesonide Alone

The New England journal of medicine, 2016-09, Vol.375 (9), p.850-860

2016

Volltextzugriff (PDF)

Comparative Effects of LAMA-LABA-ICS vs LAMA-LABA for COPD: Cohort Study in Real-World Clinical Practice

Chest, 2020-04, Vol.157 (4), p.846

2020

Volltextzugriff (PDF)

LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD

International journal of chronic obstructive pulmonary disease, 2015-01, Vol.10 (Issue 1), p.1015-1026

2015

Volltextzugriff (PDF)

Pharmacological Profile of AZD8871 (LAS191351), a Novel Inhaled Dual M 3 Receptor Antagonist/ β 2 -Adrenoceptor Agonist Molecule with Long-Lasting Effects and Favorable Safety Profile

The Journal of pharmacology and experimental therapeutics, 2019-07, Vol.370 (1), p.127

2019

Volltextzugriff (PDF)

The effect of exacerbation history on outcomes in the IMPACT trial

The European respiratory journal, 2020-05, Vol.55 (5), p.1901921

2020

Volltextzugriff (PDF)

Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy

European journal of pharmacology, 2015-08, Vol.761, p.168-173

2015

Volltextzugriff (PDF)

The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease

Pulmonary pharmacology & therapeutics, 2015-06, Vol.32, p.53-59

2015

Volltextzugriff (PDF)

Pharmacological Characterization of a Novel 5-Hydroxybenzothiazolone-Derived β 2 -Adrenoceptor Agonist with Functional Selectivity for Anabolic Effects on Skeletal Muscle Resulting in a Wider Cardiovascular Safety Window in Preclinical Studies

The Journal of pharmacology and experimental therapeutics, 2019-05, Vol.369 (2), p.188

2019

Volltextzugriff (PDF)

Pharmacological mechanisms leading to synergy in fixed-dose dual bronchodilator therapy

Current opinion in pharmacology, 2018-06, Vol.40, p.95-103

2018

Volltextzugriff (PDF)

Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study

Respiratory research, 2014-10, Vol.15 (1), p.123-123, Article 123

2014

Volltextzugriff (PDF)

In vitro and in vivo preclinical profile of abediterol (LAS100977), an inhaled long-acting β2-adrenoceptor agonist, compared with indacaterol, olodaterol and vilanterol

European journal of pharmacology, 2016-01, Vol.770, p.61-69

2016

Volltextzugriff (PDF)

Combination of budesonide/formoterol on demand improves asthma control by reducing exercise-induced bronchoconstriction

Thorax, 2014-02, Vol.69 (2), p.130-136

2014

Volltextzugriff (PDF)

Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study

Thorax, 2015-04, Vol.70 (4), p.311-319

2015

Volltextzugriff (PDF)

New combination bronchodilators for chronic obstructive pulmonary disease: current evidence and future perspectives

British journal of clinical pharmacology, 2015-05, Vol.79 (5), p.695-708

Singh, Dave

2015

Volltextzugriff (PDF)

Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal

International journal of chronic obstructive pulmonary disease, 2018-01, Vol.13, p.3971-3981

2018

Volltextzugriff (PDF)

Use of asthma medication during pregnancy and risk of specific congenital anomalies: A European case-malformed control study

Journal of allergy and clinical immunology, 2015-12, Vol.136 (6), p.1496-1502.e7

2015

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD

Controlled Trial of Budesonide–Formoterol as Needed for Mild Asthma

Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease

Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma

Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial

Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPD

Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD)

Effect of intravenous β-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trial

β₂-Adrenergic agonists augment air pollution-induced IL-6 release and thrombosis

Serious Asthma Events with Budesonide plus Formoterol vs. Budesonide Alone

Comparative Effects of LAMA-LABA-ICS vs LAMA-LABA for COPD: Cohort Study in Real-World Clinical Practice

LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD

Pharmacological Profile of AZD8871 (LAS191351), a Novel Inhaled Dual M 3 Receptor Antagonist/ β 2 -Adrenoceptor Agonist Molecule with Long-Lasting Effects and Favorable Safety Profile

The effect of exacerbation history on outcomes in the IMPACT trial

Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy

The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease

Pharmacological Characterization of a Novel 5-Hydroxybenzothiazolone-Derived β 2 -Adrenoceptor Agonist with Functional Selectivity for Anabolic Effects on Skeletal Muscle Resulting in a Wider Cardiovascular Safety Window in Preclinical Studies

Pharmacological mechanisms leading to synergy in fixed-dose dual bronchodilator therapy

Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study

In vitro and in vivo preclinical profile of abediterol (LAS100977), an inhaled long-acting β2-adrenoceptor agonist, compared with indacaterol, olodaterol and vilanterol

Combination of budesonide/formoterol on demand improves asthma control by reducing exercise-induced bronchoconstriction

Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study

New combination bronchodilators for chronic obstructive pulmonary disease: current evidence and future perspectives

Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal

Use of asthma medication during pregnancy and risk of specific congenital anomalies: A European case-malformed control study

Suchergebnisse filtern